Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP))(Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP)))

概要

基本信息

药物类型

细胞疗法

别名

Bone Marrow Mononuclear Cells(Assistance Publique–Hôpitaux de Paris (AP-HP))

靶点-

作用机制

细胞替代物

治疗领域

心血管疾病

在研适应症-

非在研适应症

慢性肢体威胁性缺血下肢缺血

原研机构

Eske Corp. SAC

在研机构-

非在研机构

Assistance Publique des Hôpitaux de Paris SA

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP)) 相关的临床试验

JPRN-jRCTb050240078 / RecruitingN/AIIT

Therapeutic angiogenesis using bone marrow-derived mononuclear cells implantation for chronic limb-threatening ischemia with arteriosclerotic obliterans - Therapeutic angiogenesis using bone marrow-derived mononuclear cells implantation for chronic limb-threatening ischemia with arteriosclerotic obliterans

开始日期2024-07-01

申办/合作机构-

NCT02494492 / Suspended临床1/2期IIT

Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose

Uveitis is a leading cause of blindness in the children and young adult's populations. One third of etiology are idiopathic. The reference treatments are corticosteroids and immunosuppressive agents. They have significant side effects, and patient's compliance is often poor. In addition, some uveitis are more resistant. Also, in these situations of deadlock therapeutic, investigators propose a cell therapy by administering regulatory T cells (Tregs) in the vitreous of patients.

开始日期2013-03-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT01325636 / Completed临床1/2期IIT

Injection of CD4 and CD8 + T Cells Anti-CMV or Anti-adenovirus for the Treatment of Viral Infections Occurring After Allogenic Hematopoietic Stem Cell Transplantation (HSCT)

The main purpose of this project is to evaluate the efficiency of the injection of CD4 and CD8+ T cell anti-Cytomegalovirus (CMV) on blood viral replication of CMV, 21 days after the first injection (adenovirus infection is not enough usual, especially in adults, to be used for the primary purpose and is measured in the secondary endpoints).

开始日期2010-09-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

100 项与 Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP)) 相关的临床结果

登录后查看更多信息

100 项与 Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP)) 相关的转化医学

登录后查看更多信息

100 项与 Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP)) 相关的专利（医药）

登录后查看更多信息

100 项与 Cell therapy(Assistance Publique–Hôpitaux de Paris (AP-HP)) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肢体威胁性缺血	临床1期	法国	Assistance Publique des Hôpitaux de Paris SA	2005-01-01
下肢缺血	临床1期	法国	Assistance Publique des Hôpitaux de Paris SA	2005-01-01